Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Acute Leukemias
This is the third volume in this series on methods of treating acute leukemia. Multiple drug resistance is discussed, along with the use of human granulocyte-macrophage CSF, the role of stem cell factor, and basic aspects of cell biology and pharmakokinetics. There is also a comprehensive section dealing with relapse therapy and postremission therapy. The book thus provides the clinician with guidelines for use in everyday practice.
Drug Resistance in Leukemia and Lymphoma III
Cellular drug resistance is a major limitation to the success of chemotherapy of leu kemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Am sterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998. The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts...
Histopathology of Nodal and Extranodal Non-Hodgkin’s Lymphomas
During the 10 years since the last edition of this volume our knowledge on malignant lymphomas, especially on extranodal lymphomas, has increased. This volume is an expanded and completely revised edition, now based on the WHO classification. The parallels to the updated Kiel classification and the REAL classification are indicated. The information is organized in organ-specific chapters, comprising the well-known nodal lymphoma entities as well as all known extranodal lymphomas and the different organ-specific clinico-pathological entities: lymphomas of the spleen, the gastrointestinal tract, the skin, etc. In addition to the morphology, the major immunohistochemical, molecular genetic, and clinical data are included in each chapter.
New Aspects in the Diagnosis and Treatment of Hodgkin’s Disease
In the field of Hodgkin's lymphoma, many new data have been collected during the last decade both on the cell of origin of this disease and on more effective therapies to cure the majority of pa tients even in the advanced stages. Therefore, it seems to be justi fied to compile these new data in a special volume of Recent Re sults in Cancer Research. This volume summarizes the contribu tions presented at the First International Symposium on Hodgkin's Disease that took place in Cologne (FRG) on October 2-3, 1988. There is little doubt that the Hodgkin and Reed-Sternberg (H and RS) cells and their variants represent the malignant population in Hodgkin's lymphoma; however, there is still a fierce debate as to the possible cell of origin of Hand RS cells. Many of the problems confounding earlier research into this question were related to the difficulty or virtual impossibility, of obtaining purified populations of Hand RS cells. Most of the recent progress stems from the establishment of permanent cell lines of Hand RS cells in culture.
Acute Leukemias VII
The 7th volume of the book series Acute Leukemias provides new updates on the biology of acute leukemias and especially the underlying genetic and molecular events. High quality contributions are provided by leading scientists and clinicians making the book an excellent overview over most recent achievements which translate into new treatment strategies and hence an improved outlook for patients suffering from acute leukemias.
Biological Roles and Function of Modification
Biological Roles and Function of Modification
Frontiers in Cardiovascular Drug Discovery
Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest and the most important advances in Cardiovascular drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in cardiovascular drug design and discovery. Each volume is devoted to the major advances in cardiovascular drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.
Acute Leukemias II
Acute leukemia a quite homogenous disease failed to break through the sound barriere of when untreated reveals a substantial hetero unsatisfactory cure rates even in special sub geneity in its response to therapy. While cure groups. While new protocols including more is achieved in a certain proportion of pa effective supportive care show some increase tients other cases prove to be highly resis in the initial response rates and certain im tant. The curability is superior in acute provements in the long-term results, no ben lymphoblastic (ALL) than in acute myeloid eficial effect on the relapse rate during the (AML) leukemia and - within both type- first 1 Y2 years emerged from any of these higher in children as compared to adults. regimens. Thus, high chances for cure are The two age groups and cell types can be presently restricted to children with ALL further subdivided into prognostic groups and to lesser proportions children with by special diagnostic features. Thus, in AML and adults with ALL and AML.
